TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') today announced that the Third Fermentation Building (provisional name) will be constructed as a new manufacturing facility for active pharmaceutical ingredient (API) of Prograf (generic name: tacrolimus hydrate) in the Toyama Technology Center of Astellas Pharma Tech Co., Ltd., a production subsidiary of Astellas.
Prograf is an immunosuppressant discovered and developed by Astellas and currently marketed in approximately 100 countries / areas. It has greatly contributed to medical transplantation globally as a first-line immunosuppressant for organ transplantation. Sales of Prograf was JPY195.7 billion in FY2018.
Astellas is currently manufacturing API of Prograf for Japan and overseas as well as formulating and packaging in the Toyama Technology Center. The purpose of the construction of the Third Fermentation Building is to enhance our production capacity that will enable a stable supply of high-quality products in the future, taking into account the expected steady demand for Prograf and the status of the existing manufacturing facility in the Toyama Technology Center. It will also have state-of-the-art facilities based on the efficiency of the existing facilities.
The total construction cost will be approximately JPY10.0 billion, and the facility will have three above-ground floors and a total floor area of approximately 7,220 m2. The construction will be commenced in April 2020 and the completion is scheduled in August 2021.
This investment will have no impact on the financial results for the FY2019 ending March 31, 2020.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
(C) 2020 Electronic News Publishing, source ENP Newswire